Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-06-09
2010-11-23
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S559000, C514S576000, C514S578000
Reexamination Certificate
active
07838554
ABSTRACT:
The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
REFERENCES:
patent: 3152148 (1964-10-01), Easterly et al.
patent: 3441605 (1969-04-01), Blake et al.
patent: 3773946 (1973-11-01), Creger
patent: 3930024 (1975-12-01), Creger
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4584321 (1986-04-01), Manghisi et al.
patent: 4613593 (1986-09-01), Yamatsu et al.
patent: 4634719 (1987-01-01), Takaishi et al.
patent: 4689344 (1987-08-01), Bar-Tana
patent: 4711896 (1987-12-01), Bar-Tana et al.
patent: 4714762 (1987-12-01), Hoefle et al.
patent: 5166174 (1992-11-01), Ueno et al.
patent: 5225439 (1993-07-01), Ueno et al.
patent: 5284858 (1994-02-01), Ueno et al.
patent: 5380709 (1995-01-01), Ueno et al.
patent: 5428062 (1995-06-01), Ueno et al.
patent: 5502198 (1996-03-01), Picard et al.
patent: 5504073 (1996-04-01), Homan
patent: 5578639 (1996-11-01), Homan
patent: 5633287 (1997-05-01), Lee et al.
patent: 5648387 (1997-07-01), Bisgaier et al.
patent: 5750569 (1998-05-01), Bisgaier et al.
patent: 5756344 (1998-05-01), Onda et al.
patent: 5756544 (1998-05-01), Bisgaier et al.
patent: 5783600 (1998-07-01), Bisgaier et al.
patent: 5834596 (1998-11-01), Ageland et al.
patent: 5886034 (1999-03-01), Ueno et al.
patent: 5968963 (1999-10-01), Homan
patent: 5981595 (1999-11-01), Picard et al.
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6017905 (2000-01-01), Roark et al.
patent: 6037323 (2000-03-01), Dasseux et al.
patent: 6093719 (2000-07-01), Bocan
patent: 6093744 (2000-07-01), Lee et al.
patent: 6124309 (2000-09-01), Bocan
patent: 6143755 (2000-11-01), Bocan
patent: 6284903 (2001-09-01), Bar-Tana
patent: 6459003 (2002-10-01), Dasseux et al.
patent: 6646170 (2003-11-01), Dasseux et al.
patent: 6673780 (2004-01-01), Dasseux et al.
patent: 6699910 (2004-03-01), Dasseux et al.
patent: 6703422 (2004-03-01), Dasseux et al.
patent: 6713507 (2004-03-01), Dasseux et al.
patent: 2004/0209847 (2004-10-01), Dasseux et al.
patent: 2005/0043278 (2005-02-01), Dasseux et al.
patent: 0 284 108 (1987-09-01), None
patent: 1 545 224 (1968-11-01), None
patent: 1196594 (1970-07-01), None
patent: 1196595 (1970-07-01), None
patent: 1196596 (1970-07-01), None
patent: 1196597 (1970-07-01), None
patent: 1196598 (1970-07-01), None
patent: WO 98/30328 (1998-07-01), None
patent: WO 98/30530 (1998-07-01), None
patent: WO 99/00116 (1999-01-01), None
Bicking, et al., “11,12-Secoprostaglandins. 1. Acylhydroxyalkanoic acids and related compounds”, J. Med. Chem., 1977, pp. 35-43, vol. 20.
Nagano H, et al., “Stereoselectivity in the formation and radical reduction of cyclic bromoacetals, key intermediates for the synthesis of delta-hydroxy-and epsilon-hydroxy-alpha-methylcarboxylic acid esters”, Tetrahedron Letters, 2003, pp. 6867-6870, vol. 44, No. 36.
Bobrova, et al., abstract, J. Org. Chem. 1983, pp. 259-261, vol. 19.
Narasaka, et al., abstract, Bull. Chem. Soc, 1987, pp. 1457-1464, vol. 60, No. 4.
Rieke, et al., abstract, J. Org. Chem, 1996, pp. 2726-2730, vol. 61, No. 8.
Pechmann, abstract, Chem. Ber., 1904, p. 3819, vol. 37.
Lardelli, et al., abstract, Recl. Trav. Chim., 1967, pp. 481-503, vol. 86.
Crisan, abstract, Ann. Chim., 1956, pp. 436-459, vol. 13, No. 1.
Blatt, et al., The reducing action of the Grignard reagent and the synthesis of tertiary aliphatic carbinols, J. Org. Chem., 1932, pp. 1495-1499, vol. 54.
Brown, et al., “Hydroboration. 67. Cyclic hydroboration of acyclic alpha, omega-dienes with 9-Borabicyclo '3.3.1 Inonane/borane-dimethyl sulfide”, J. Org. Chem., pp. 1072-1078, vol. 49, No. 6 (1984).
Weber, et al., abstract, J. Med. Chem., 1992, pp. 3755-3773, vol. 35, No. 21.
Yamamoto, “Asymmetric synthesis of 5-and 6-membered lactones from cyclic substrates bearing a c2-chiral auxiliary”, 1. Org. Chem., 1991, pp. 1112-1119, vol. 35, No. 21.
Ooi T, et al., abstract, Angewandte Chemie., 2001, vol. 40, No. 19.
English, J. Am. Chem. Soc., 1941, p. 942, vol. 63.
Gleiter, et al., “Synthesis of 5,5,10,10-tetramethy1-1-oxacyclotridecane-6,7,8,9-tetrone-on the mechanism of the Rubottom reaction”, 1995, (9), pp. 1655-1661.
Gleiter, et al., “Synthesis and properties of 4,4,9,9-tetramethyl-1-oxa-cycloundecane-5,6,7,8-tetrone and 9-tetramethyl-1-oxa-cyclotridecane-6,7,8,9-tetrone”, 1996, 2(3), pp. 271-277.
Momenteau, et al., abstract, J. Chem Soc. Perkin Trans. 1985, pp. 221-232.
Corey et al., 1967, “A useful method for conversion of alcohols into iodides”, J. Org. Chem, 32: 4160-4161.
Taravel et al., 1988, “Interglycosidic13C-1H Coupling Constants” Tetrahedeon Lett, 29:199-200.
Vamecq and Draye, 1989, “Pathophysiology of peroxisomal beta-oxidation”, Essays Biochem, 24: 115-225.
Silverman, The Organic Chemistry of Drug Design and Drug Interaction, 1992, pp. 15-22.
Bohme. V. and Lener. W., 1955. Annalen der Chemie, 595:169-178 (English language abstract).
Xu et al., 1989, “The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells”, Oncogene 4: 807-812.
Ackerly, et al., 1995, “A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dloxane-thrombaxane receptor antagonists and -thromboxane synthase inhibitors”, J. Med. Chem. 38:1608-1628.
Acton et al., 1996, “Identification of scavenger receptor SR-BI as a high density lipoprotein receptor”, Science. 271(5248):518-20.
Ahrens et al., 1967, A direct method for preparing pyridoxal and 4-pyridoxic acid (1), J. Heterocycl. Chem. 4:625-26.
Alexander, K et al., 1948, “4,4′-Dichlorodibutyl ether and its derivatives from tetrahydrofuran”, J. Am. Chem. Soc. 70: 1839-42.
Badimon et al., 1992, “Role of High density lipoproteins In the regression of atherosclerosis”, Circulation 86 (Suppl):11186-94.
Bailey, et al.,1990, “Convenient general method for the preparation of primary aikeylllthiums by lithium-iodine exchange”, J. Org. Chem. 55:5404-06.
Barrans et al., 1996, “Pre-beta HDL; structure and metabolism”, Biochim. Biophys. Acta. 1300(2):73-85.
Becker et al., 1982, “Intramolecular photoaddition of terminal allenes to conjugated cyclohexenones”, J. Org. Chem.47:3297-3310.
Bernady et al.,1979. “Prostaglandins and congeners. 20 .. sup.1,2 Synthesis of prostaglandins via conjugate addition of lithium trans-1-alkenyltrialkylalanate reagents. A novel reagent for conjugate 1,4-additions”, J. Org. Chem. 44:1438-47.
Bhanot et al.,1977, “Synthetic Studies on Terpenoids.5.Syntheses of .gamma.- and delta.-Lactones from. beta .-(2,7 -Dimethyl-1,2-dihydroxycycloheptyl)propionic Acid”, J. Org. Chem. 42:1623-1627.
Bisgaier et al.,1998, “A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor”, J Lipid Res. 39(1):17-30.
Bisgaier et al..1997, Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3- methyl
Dasseux Jean-Louis Henri
Oniciu Carmen Daniela
Brinks Hofer Gilson & Lione
Esperion Therapeutics, Inc.
Zucker Paul A
LandOfFree
Dihydroxyl compounds and compositions for cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydroxyl compounds and compositions for cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydroxyl compounds and compositions for cholesterol... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192382